Artiva Biotherapeutics Raises $ 120 Million in Series B Funding to Advance NK Cell-Based Allogeneic…
SAN DIEGO - (COMMERCIAL THREAD) -Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company that develops cell therapies based on natural killer primary allogeneic (NK) cells optimized for their ability to kill…